uniQure to Participate in Multiple Upcoming Industry Conferences in March

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced its participation in various investor and scientific conferences in March 2023. Key events include the Cowen Annual Healthcare Conference from March 6-8 in Boston, where CEO Matt Kapusta will engage in one-on-one meetings and a panel discussion.

Other conferences include the Bioprocessing Summit Europe on March 15 in Barcelona, the Huntington's Disease Youth Organization Congress from March 17-19 in Glasgow, and the MDA Conference from March 19-22 in Austin. The company aims to showcase its advancements in gene therapy, particularly for severe medical conditions like hemophilia B.

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

• Cowen Annual Healthcare Conference, March 6 – 8, 2023 Boston, MA
  
  
  • Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in one-on-one investor meetings on Monday, March 6.
    
    
  • Mr. Kapusta also will participate in a panel discussion, “Genetic Medicines Corporate Panel,” on March 6 from 10:30 – 11:30 a.m. ET. The live webcast of this event can be accessed through the link displayed in the Investors & Media section of the uniQure website.
    
    
• Bioprocessing Summit Europe, March 15, 2023 Barcelona, Spain
  
  
  • Hugo Rojas, Ph.D., associate director in drug substance development, will deliver an encore presentation discussing our high-throughput scale-down model enabling fast USP development in gene therapy.
    
    
• Huntington’s Disease Youth Organization (HDYO) International Young Adults Congress, March 17 – 19, 2023 Glasgow, Scotland
  
  
  • Astrid Vallez-Sanchez, Ph.D., director of global research, will participate in an informational session: “Gene Therapy – A Closer Look” on Saturday, March 18 at 11:20 a.m. GMT.
    
    
• Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19 – 22, 2023 Austin, TX
  
  
  • Meg Bradbury, M.S., CGC, MSHS, director of clinical translation, will present a pre-recorded overview on both AMT-162, a clinical-stage gene therapy candidate in SOD1 amyotrophic lateral sclerosis (ALS),   and AMT-161, a preclinical gene therapy candidate in c9orf72 ALS mutation on Tuesday, March 21.
    

• Academy of Managed Care Pharmacy (AMCP) Conference, March 21 – 24, 2023 San Antonio, TX
  
  
  • Frank Zhang, M.D., M.P.H., vice president of commercial, will present an encore poster on the employment impacts of early manifest Huntington’s disease in adults.
    
    
• Stifel Virtual CNS Days, March 28, 2023
  
  
  • Members of uniQure’s management team will participate in virtual investor meetings on Tuesday, March 28.
    
    
  • A fireside chat with Matt Kapusta will take place the same day from 11:30 – 11:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Media section of the uniQure website.
    
    
• International Conference on Alzheimer’s & Parkinson’s Disease (AD/PD), March 28 – April 1, 2023 Gothenburg, Sweden
  
  
  • Amila Zuko, Ph.D., scientist in adult neurology, will deliver an oral presentation on preclinical mouse data on an intrastriatally delivered AAV product candidate focused on a combination approach of increasing protective APOE variants and lowering toxic APOE variants as a therapy for Alzheimer Disease.
    

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represents a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology platform to advance a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:                       

FOR INVESTORS:	FOR MEDIA:
Chiara Russo	Tom Malone
Direct: 617-306-9137	Direct: 339-970-7558
Mobile: 617-306-9137	Mobile:339-223-8541
c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What conferences is uniQure participating in March 2023?

uniQure is participating in several conferences, including the Cowen Annual Healthcare Conference, Bioprocessing Summit Europe, Huntington's Disease Youth Organization Congress, and the MDA Clinical & Scientific Conference.

Who will represent uniQure at the Cowen Annual Healthcare Conference?

Matt Kapusta, CEO of uniQure, will represent the company, participating in one-on-one investor meetings and a panel discussion.

What topics will uniQure present at the MDA Clinical & Scientific Conference?

At the MDA Conference, Meg Bradbury will present an overview of the gene therapy candidates AMT-162 and AMT-161 on March 21.

What is the focus of uniQure's gene therapy advancements?

uniQure is focused on gene therapies for severe medical conditions, including Huntington's disease and ALS, and has recently achieved success with its gene therapy for hemophilia B.

When is the International Conference on Alzheimer’s & Parkinson’s Disease?

The International AD/PD Conference is scheduled for March 28 to April 1, 2023, in Gothenburg, Sweden.